ReviewThe Lancet. Infectious diseases2021

Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections.

A Sarah Walker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.